A New CBD Study Investigates the CBD Bioavailability in Dogs

• Published August 18, 2022

• No Comments

Innocan, a leader in CBD research, recently conducted a study in collaboration with the Hebrew University of Jerusalem to investigate the bioavailability of CBD in dogs. The Israeli pharmaceutical tech company used Liposome Platform Technology (LPT) to measure the bioavailability of CBD administered to dogs experiencing discomfort. The results showed that bioavailability was nearly 100%.

The CBD was delivered via an injection into the fat layer under the dog’s skin. The 100 percent bioavailability is a remarkable finding compared to the average 6.5-2.0 percent in humans when CBD is taken orally. Orally consumed CBD must undergo first-pass metabolism (by the digestive system). This means much of the CBD is metabolized in the body before it reaches the bloodstream, where it can deliver the most benefits throughout the body.

The liposomal delivery system is a system in which an active ingredient in a drug formula is encapsulated in particles resembling fat. Innocan has been perfecting the LPT delivery system through animal experiments. The CEO of Hebrew University, Professor Chezy Barenholz, said,

“One of the challenges with CBD treatments is its pharmacokinetic profile after oral administration that is characterized by low bioavailability and fast elimination. Our preliminary data show that we may overcome these major obstacles using the LPT technology and this is very encouraging.”

The goal is to develop a CBD delivery system that increases CBD bioavailability, allowing more CBD to reach the bloodstream. Once in the bloodstream, CBD is transported throughout the body. This would enable a more effective and longer therapeutic effect for people experiencing various health conditions.

Innocan is also beginning clinical trials for new drug delivery systems. This is exciting news because the results of various clinical studies on drug delivery systems can lead to a perfected system that works with a variety of drugs, including CBD. Increasing CBD bioavailability will enable more people to take better advantage of the benefits that numerous research projects have demonstrated cannabinoids can deliver. The evidence is mounting that CBD is a powerful, safe, and effective natural ingredient for supporting well-being.

About the Author

Michael Levin

Michael Levin is a CBD enthusiast, a researcher, writer and editor in the cannabis space, experienced CBD user and educator. He believes CBD can help improve our overall health and wellbeing.

• View all posts by Michael Levin